ALEX trial results show alectinib further outpacing crizotinib in ALK+ NSCLC
Updated results of the global phase III ALEX trial comparing alectinib with crizotinib as first-line treatment against ALK-positive non-small cell lung cancer show a median progression-free survival (PFS) of 34.8 months in ...
Jun 3, 2018
0
8